Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
The new subvariant, first sampled in autumn in New York state, has a potent array of mutations that appear to help it evade immune defenses and improve its ability to invade cells. → Read More
For years, Dr. Nicholas Schiff and Dr. Emery Brown have been developing theories about what happens in the brain during comas, sleep, and anesthesia. Now they turned their efforts to COVID. Their search for clues brought them unexpectedly to studies of turtles. → Read More
The vaccine was authorized as a primary immunization series for adults, rather than a booster, which may limit its market at first. → Read More
A new study found that sabizabulin reduced the risk of death by 55 percent, but some experts were cautious about overinterpreting the results. → Read More
Before the FDA can authorize the shots, it would need to sign off on Novavax’s manufacturing process, which has stumbled again and again over the course of two years. → Read More
Clinical trials found the vaccine to work well, but the company has long struggled with manufacturing. → Read More
As the Omicron coronavirus surge subsides, researchers are keeping an eye on a highly transmissible subvariant known as BA.2. Although it doesn’t appear to have the capacity to drive a large new wave of infections, the variant could potentially slow the current decline of Covid cases and make treatments more difficult. Here’s what we know so far about BA.2. It’s not really new. Scientists first… → Read More
Scientists released a pair of extensive studies on Saturday that point to a market in Wuhan, China, as the origin of the coronavirus pandemic. The two reports, totaling about 150 pages, have not yet been published in a scientific journal. → Read More
So far, the new variant, BA.2, doesn’t appear to cause more severe disease, and vaccines are just as effective against it as they are against other forms of omicron. But it does show signs of spreading more readily. → Read More
Two shots of the vaccine reduced the risk of hospitalization from the fast-spreading variant by 85 percent, a clinical trial found. → Read More
A Harvard professor for 46 years, he was an expert on insects and explored how natural selection and other forces could influence animal behavior. He then applied his research to humans. → Read More
People who received Pfizer-BioNTech vaccines may get as much benefit from a Johnson & Johnson booster shot as a Pfizer one. That’s the finding of a small study released Sunday. → Read More
People looking for a booster shot of a COVID-19 vaccine probably don’t need to fret about what brand it is: Many combinations of shots are likely to provide strong protection, according to a large new study. → Read More
A new simulation shows how the virus survives inside tiny airborne particles of water — and gives clues about how the Delta variant became dominant. → Read More
A British clinical trial found no sign of danger in getting a flu shot and a second dose of a COVID-19 vaccine at the same time. → Read More
With $15 million in private funding, Colossal aims to bring thousands of woolly mammoths back to Siberia. Some scientists are deeply skeptical that will happen. → Read More
The companies said they will submit their data by the end of the week and ask the F.D.A. to approve a third shot. → Read More
Johnson & Johnson will submit the data to the Food and Drug Administration, which is evaluating similar data on boosters from Pfizer and Moderna. → Read More
The company said it expected boosters would still be needed before winter because of the Delta variant. And the Biden administration is planning vaccine requirements for foreign travelers. → Read More
Pfizer’s coronavirus vaccine may become slightly weaker over time, the company reported. But experts said that most people won’t need boosters anytime soon. → Read More